//fpnotebook.com/
Celecoxib
Aka: Celecoxib, Celebrex
- Class
- NSAID: COX2 Inhibitor
- Similar to Rofecoxib (Vioxx)
- Diaryl-substituted pyrazole
- Advantages
- Less gastrointestinal adverse effects than other NSAIDs
- See NSAID Gastrointestinal Adverse Effects
- Metabolism
- Oral Bioavailability: 22 to 40%
- Half Life: 11 hours
- Liver metabolism by Cytochrome P450: CYP2C9
- Levels raised with Accolate, Diflucan, and Lescol
- Inhibits Cytochrome P450: CYP2D6
- Increases levels of Beta Blockers and psychotropics
- Contraindications: Sulfonamide Allergy
- Consider alternative agent: Rofecoxib (Vioxx)
- Dosing
- Osteoarthritis: 200 mg PO qd (or 100 mg po bid)
- Rheumatoid Arthritis: 200 mg PO qd to bid
- Familial Adenoma Polyposis: 400 mg PO bid
- Adverse Effects
- Celebrex appears safer than Ibuprofen in terms of cardiovascular risk
- Ruschitzka (2017) Eur Heart J +PMID:29020251 [PubMed]
- Abdominal Pain
- Diarrhea
- Dyspepsia
- Peptic Ulcer Disease risk (see COX2 Inhibitor)
- Does not increase Bleeding Time
- References
- Michalets (1998) Pharmacotherapy 18:84 [PubMed]
- (1999) Med Lett Drugs Ther 41(1045): 11-14 [PubMed]